 |
245 Diseases |  |
389 Trials |
|
389 Trials |  |
11400 News |  |
| «12...120121122123124125126127128129130...143144» |
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Trial primary completion date, Metastases: Efficacy of Chemotherapy, Associated to Either Cetuximab or Bevacizumab, in KRAS Wild-type Metastatic Colorectal Cancer Patients With Progressive Disease After Receiving First-line Treatment With Bevacizumab (clinicaltrials.gov) - Dec 18, 2015
P2, N=132, Active, not recruiting, Sponsor: UNICANCER
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2015 --> Oct 2015
- ||| napabucasin (BBI608) / Sumitomo Pharma
Enrollment change, Metastases: A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer (clinicaltrials.gov) - Dec 17, 2015
P2, N=150, Recruiting, Sponsor: Boston Biomedical, Inc
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2015 --> Oct 2015 N=66 --> 150
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P3 trial, Metastases: Cisplatin Plus Docetaxel Versus Cetuximab, Cisplatin, and Docetaxel in Metastatic Nasopharyngeal Carcinoma (clinicaltrials.gov) - Dec 17, 2015
P3, N=120, Recruiting, Sponsor: Sun Yat-sen University
- ||||| patritumab (U3-1287) / Amgen, Daiichi Sankyo
New P2 trial, Combination therapy, Metastases: Patritumab With Cetuximab and a Platinum Agent for Squamous Cell Carcinoma (Cancer) of the Head and Neck (SCCHN ) (clinicaltrials.gov) - Dec 17, 2015
P2, N=105, Recruiting, Sponsor: Daiichi Sankyo Inc.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date: INTERCEPTOR: Induction Chemotherapy Followed by Cetuximab Plus Definitive Radiotherapy Versus Radiation Plus Cisplatin (clinicaltrials.gov) - Dec 16, 2015
P3, N=278, Recruiting, Sponsor: Gruppo Oncologico del Nord-Ovest
N=66 --> 150 Trial primary completion date: Dec 2015 --> May 2016
- ||| Piqray (alpelisib) / Novartis
Enrollment closed, Trial primary completion date, Combination therapy, Metastases: A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) - Dec 16, 2015
P2, N=177, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Dec 2015 --> May 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2016 --> Aug 2017
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial initiation date, Trial primary completion date, Metastases: AGMT_HNO_PN: Parenteral Nutrition for Patients Treated for Locally Advanced Inoperable Tumors of the Head and Neck (clinicaltrials.gov) - Dec 15, 2015
P3, N=146, Not yet recruiting, Sponsor: Arbeitsgemeinschaft medikamentoese Tumortherapie
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2016 --> Aug 2017 Initiation date: Jun 2015 --> Apr 2016 | Trial primary completion date: Jun 2018 --> Jun 2019
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Orpathys (savolitinib) / AstraZeneca, Hutchmed
New P1 trial: Cetuximab and Savolitinib Treatment of Ras Wild-Type Colorectal Cancer (clinicaltrials.gov) - Dec 15, 2015
P1, N=33, Not yet recruiting, Sponsor: Yale University
- patritumab (U3-1287) / Amgen, Daiichi Sankyo
Enrollment closed, Combination therapy, Metastases: Patritumab With Cetuximab and a Platinum Containing Therapy for Patients With Head and Neck Cancer (clinicaltrials.gov) - Dec 14, 2015
P1b, N=15, Active, not recruiting, Sponsor: Daiichi Sankyo Inc.
Initiation date: Jun 2015 --> Apr 2016 | Trial primary completion date: Jun 2018 --> Jun 2019 Recruiting --> Active, not recruiting
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, tivantinib (ARQ 197) / Daiichi Sankyo, Kyowa Kirin, Merck (MSD)
Trial primary completion date, Surgery, Metastases: Cetuximab With or Without Tivantinib in Treating Patients With Head and Neck Cancer That Is Recurrent, Metastatic, or Cannot Be Removed by Surgery (clinicaltrials.gov) - Dec 12, 2015
P2, N=76, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2015 --> May 2016
- ||||| Imprime PGG (odetiglucan) / HiberCell
Enrollment closed, Combination therapy: PRIMUS: Study of Imprime PGG (clinicaltrials.gov) - Dec 12, 2015
P3, N=795, Active, not recruiting, Sponsor: Biothera
Trial primary completion date: Dec 2015 --> May 2016 Recruiting --> Active, not recruiting
- ||| simlukafusp alfa (RG7461) / Roche, Herceptin (trastuzumab) / Roche
New P1 trial, Combination therapy: A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C) (clinicaltrials.gov) - Dec 10, 2015
P1, N=60, Recruiting, Sponsor: Hoffmann-La Roche
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date, Combination therapy, Metastases: Everest 2: Cetuximab Standard or Dose Escalation in First Line Colorectal Cancer (clinicaltrials.gov) - Dec 10, 2015
P2, N=375, Active, not recruiting, Sponsor: Universitaire Ziekenhuizen Leuven
Recruiting --> Active, not recruiting Trial primary completion date: Mar 2015 --> Mar 2016
- Keytruda (pembrolizumab) / Merck (MSD)
Trial primary completion date, Metastases: Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer (clinicaltrials.gov) - Dec 10, 2015
P1/2, N=90, Recruiting, Sponsor: Western Regional Medical Center
Trial primary completion date: Mar 2015 --> Mar 2016 Trial primary completion date: Oct 2015 --> Oct 2017
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P2 trial, Metastases: V-CHANCE: Valproic Acid Plus Cisplatin and Cetuximab in Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck (clinicaltrials.gov) - Dec 9, 2015
P2, N=39, Recruiting, Sponsor: National Cancer Institute, Naples
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date, Metastases: Radiation and Cetuximab Plus Intratumoral EGFR Antisense DNA in Locally Advanced Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) - Dec 6, 2015
P1/2, N=42, Active, not recruiting, Sponsor: Woondong Jeong
Trial primary completion date: Oct 2015 --> Oct 2017 Trial primary completion date: Nov 2015 --> Jan 2024
- gedatolisib (PF-05212384) / Celcuity
Trial primary completion date, Metastases: A Study Of PF-05212384 Plus Irinotecan Vs Cetuximab Plus Irinotecan In Patients With KRAS And NRAS Wild Type Metastatic Colorectal Cancer (clinicaltrials.gov) - Dec 5, 2015
P2, N=150, Terminated, Sponsor: Pfizer
Trial primary completion date: Nov 2015 --> Jan 2024 Trial primary completion date: Nov 2015 --> May 2016
- |||| Imbruvica (ibrutinib) / AbbVie, J&J
Enrollment open, Combination therapy, Metastases: Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors (clinicaltrials.gov) - Dec 5, 2015
P1/2, N=189, Recruiting, Sponsor: Pharmacyclics
Trial primary completion date: Nov 2015 --> May 2016 Not yet recruiting --> Recruiting
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Trial primary completion date, Surgery: Re-irradiation With Fractionated Stereotactic Radiosurgery Plus Cetuximab in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov) - Dec 5, 2015
P2, N=59, Active, not recruiting, Sponsor: University of Pittsburgh
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Dec 2016
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Trial primary completion date, Metastases: Combination of Irinotecan, Oxaliplatin and Cetuximab for Locally Advanced or Metastatic Pancreatic Cancer (clinicaltrials.gov) - Dec 5, 2015
P2, N=61, Completed, Sponsor: New Mexico Cancer Care Alliance
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Dec 2016 Active, not recruiting --> Completed | Trial primary completion date: Dec 2016 --> Apr 2015
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen
Trial primary completion date, Metastases: PACER: A Phase 2 Study of Panitumumab in Patients With Cetuximab-refractory Metastatic Colorectal Cancer (clinicaltrials.gov) - Nov 30, 2015
P2, N=41, Recruiting, Sponsor: National Cancer Institute, Naples
Active, not recruiting --> Completed | Trial primary completion date: Dec 2016 --> Apr 2015 Trial primary completion date: Jul 2015 --> Jul 2016
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date, Metastases: Paclitaxel, Carboplatin and Cetuximab (PCC) With Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) - Nov 26, 2015
P2, N=128, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Jul 2015 --> Jul 2016 Trial primary completion date: Jul 2016 --> Jul 2017
- |||| Opdivo (nivolumab) / BMS
Trial primary completion date, Metastases: Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141) (clinicaltrials.gov) - Nov 21, 2015
P3, N=360, Recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Jul 2016 --> Jul 2017 Trial primary completion date: Jul 2016 --> Oct 2016
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date, Metastases: Efficacy and Tolerance of Maintenance Therapy in Patients With Incurable Advanced Colorectal Cancer (clinicaltrials.gov) - Nov 19, 2015
P2, N=54, Recruiting, Sponsor: Tianshu Liu
Trial primary completion date: Jul 2016 --> Oct 2016 Trial primary completion date: Feb 2016 --> May 2016
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date, Metastases: Study of Radiation (RT) Concurrent With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (SCC) (clinicaltrials.gov) - Nov 19, 2015
P2, N=50, Recruiting, Sponsor: University of Michigan Cancer Center
Trial primary completion date: Feb 2016 --> May 2016 Trial primary completion date: Feb 2016 --> May 2016
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Combination therapy: Cetuximab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Unresectable Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer (clinicaltrials.gov) - Nov 16, 2015
P2, N=0, Completed, Sponsor: Radiation Therapy Oncology Group
Trial primary completion date: Feb 2016 --> May 2016 Active, not recruiting --> Completed
- |||||| Imjudo (tremelimumab) / AstraZeneca, Pfizer, Imfinzi (durvalumab) / AstraZeneca
Enrollment open, Trial primary completion date, Combination therapy, Metastases: KESTREL: Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer (clinicaltrials.gov) - Nov 16, 2015
P3, N=628, Recruiting, Sponsor: AstraZeneca
Active, not recruiting --> Completed Not yet recruiting --> Recruiting | Trial primary completion date: Nov 2018 --> Nov 2017
- |||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Trial primary completion date, Metastases: Pre-op Rectal ChemoRad +/- Cetuximab (clinicaltrials.gov) - Nov 11, 2015
P2, N=139, Completed, Sponsor: US Oncology Research
Not yet recruiting --> Recruiting | Trial primary completion date: Nov 2018 --> Nov 2017 Active, not recruiting --> Completed | Trial primary completion date: Jun 2015 --> Jan 2015
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial suspension, Metastases: COMMENCE: A Study of the Combination of Cetuximab and Methotrexate in Recurrent or Metastatic Cancer of the Head and Neck (clinicaltrials.gov) - Nov 11, 2015
P1/2, N=120, Suspended, Sponsor: Radboud University
Active, not recruiting --> Completed | Trial primary completion date: Jun 2015 --> Jan 2015 Recruiting --> Suspended
- ||| Zelboraf (vemurafenib) / Roche
Enrollment closed, Enrollment change: A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers (clinicaltrials.gov) - Nov 10, 2015
P2, N=208, Active, not recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Suspended Recruiting --> Active, not recruiting | N=160 --> 208
- || lumretuzumab (RG7116) / Roche
Enrollment closed, Trial primary completion date, Combination therapy, Metastases: A Study of RO5479599 Alone or in Combination With Cetuximab or Erlotinib in Participants With Metastatic and/or Locally Advanced Malignant Human Epidermal Growth Factor Receptor (HER3) Expressing Solid Tumors of Epithelial Cell Origin (clinicaltrials.gov) - Nov 10, 2015
P1, N=184, Active, not recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting | N=160 --> 208 Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2016 --> May 2016
- ||||| Imbruvica (ibrutinib) / AbbVie, J&J
New P1/2 trial, Combination therapy, Metastases: Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors (clinicaltrials.gov) - Nov 8, 2015
P1/2, N=189, Not yet recruiting, Sponsor: Pharmacyclics
- ||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, urelumab (BMS-663513) / BMS, Ono Pharma
Enrollment open, Enrollment change, Combination therapy, Metastases: Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer (clinicaltrials.gov) - Oct 30, 2015
P1, N=104, Recruiting, Sponsor: Bristol-Myers Squibb
Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2016 --> May 2016 Active, not recruiting --> Recruiting | N=64 --> 104
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono, urelumab (BMS-663513) / BMS, Ono Pharma
Enrollment closed, Enrollment change, Combination therapy, Metastases: Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer (clinicaltrials.gov) - Oct 29, 2015
P1, N=64, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Recruiting | N=64 --> 104 Recruiting --> Active, not recruiting | N=104 --> 64
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date, Metastases: Study of Oxaliplatin and Xeloda and Cetuximab as First Line Treatment for Metastatic or Unresectable Gastric or Gastroesophageal Junction Cancer (clinicaltrials.gov) - Oct 27, 2015
P2, N=75, Active, not recruiting, Sponsor: University of Southern California
Recruiting --> Active, not recruiting | N=104 --> 64 Trial primary completion date: Jan 2015 --> Jun 2016
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen, Takeda
Enrollment closed: Safety, Tolerability and Efficacy Study of Doxycycline Foam for the Prevention of EGFRI Skin Toxicity in Cancer Patients (clinicaltrials.gov) - Oct 27, 2015
P2, N=24, Active, not recruiting, Sponsor: Foamix Ltd.
Trial primary completion date: Jan 2015 --> Jun 2016 Recruiting --> Active, not recruiting
- |||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Metastases: Study of Gemcitabine/Platinum +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov) - Oct 27, 2015
P2, N=120, Completed, Sponsor: Eli Lilly and Company
Recruiting --> Active, not recruiting No longer recruiting --> Completed
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed: Super-Selective Intraarterial Cerebral Infusion of Cetuximab (Erbitux) for Treatment of Relapsed/Refractory GBM and AA (clinicaltrials.gov) - Oct 26, 2015
P1, N=30, Active, not recruiting, Sponsor: North Shore Long Island Jewish Health System
No longer recruiting --> Completed Recruiting --> Active, not recruiting
- |||| tivantinib (ARQ 197) / Daiichi Sankyo, Kyowa Kirin, Merck (MSD)
Trial completion, Combination therapy, Metastases: ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Oct 23, 2015
P1/2, N=150, Completed, Sponsor: Daiichi Sankyo Inc.
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- || Stivarga (regorafenib) / Bayer
Trial primary completion date, Combination therapy, Metastases: Safety and Pharmacokinetics of Regorafenib and Cetuximab in Combination (clinicaltrials.gov) - Oct 23, 2015
P1, N=54, Recruiting, Sponsor: Bayer
Active, not recruiting --> Completed Trial primary completion date: Jan 2016 --> Aug 2016
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen, Takeda
Trial primary completion date: S1013: Validation of Cancer Questionnaire for Skin Toxicities in Patients With Colorectal Cancer or Lung Cancer Receiving Cetuximab, Panitumumab, or Erlotinib Hydrochloride (clinicaltrials.gov) - Oct 23, 2015
P=N/A, N=140, Recruiting, Sponsor: Southwest Oncology Group
Trial primary completion date: Jan 2016 --> Aug 2016 Trial primary completion date: Nov 2015 --> Nov 2016
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment open: NoTOPain: Novel Treatment Option for Neuropathic Pain (clinicaltrials.gov) - Oct 23, 2015
P2, N=14, Recruiting, Sponsor: Sorlandet Hospital HF
Trial primary completion date: Nov 2015 --> Nov 2016 Not yet recruiting --> Recruiting
- || Tabrecta (capmatinib) / Incyte, Novartis
Trial primary completion date, Combination therapy: Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy (clinicaltrials.gov) - Oct 22, 2015
P1/2, N=60, Recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Trial primary completion date: Aug 2016 --> Feb 2017
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono, motolimod (VTX 2337) / BMS
Trial primary completion date, Combination therapy, Metastases: Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov) - Oct 22, 2015
P2, N=175, Active, not recruiting, Sponsor: VentiRx Pharmaceuticals Inc.
Trial primary completion date: Aug 2016 --> Feb 2017 Trial primary completion date: Sep 2015 --> Sep 2016
- || napabucasin (BBI608) / Sumitomo Pharma
Trial primary completion date, Metastases: A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer (clinicaltrials.gov) - Oct 22, 2015
P2, N=66, Recruiting, Sponsor: Boston Biomedical, Inc
Trial primary completion date: Sep 2015 --> Sep 2016 Trial primary completion date: Dec 2015 --> Jun 2016
- ||||| cisplatin / Generic mfg., albumin-bound paclitaxel / Generic mfg.
New P2 trial, Metastases: Nab-Paclitaxel and Cisplatin or Nab-paclitaxel as Induction Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC) (clinicaltrials.gov) - Oct 22, 2015
P2, N=80, Not yet recruiting, Sponsor: Washington University School of Medicine
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P1 trial, Combination therapy, Metastases: Irinotecan Hydrochloride With FOLFIRI and Cetuximab as First-Line Therapy in Treating Patients With RAS Wild-Type Colorectal Cancer (clinicaltrials.gov) - Oct 22, 2015
P1, N=45, Not yet recruiting, Sponsor: University of Chicago
- || Ojemda (tovorafenib) / Day One Biopharma, alisertib (MLN8237) / Puma
Enrollment change, Trial primary completion date, Combination therapy, Metastases: A Study MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic Malignancies (clinicaltrials.gov) - Oct 22, 2015
P1b, N=125, Recruiting, Sponsor: Millennium Pharmaceuticals, Inc.
Trial primary completion date: Dec 2015 --> Jun 2016 N=103 --> 125 | Trial primary completion date: Jun 2017 --> Jun 2016
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Trial termination, Trial primary completion date: A Randomised Trial With Irinotecan, Cetuximab and Everolimus (ICE)Compared to Capecitabine and Oxaliplatin (CapOx) for Patients With Gemcitabin Resistant Pancreatic Cancer (clinicaltrials.gov) - Oct 22, 2015
P1/2, N=39, Terminated, Sponsor: Per Pfeiffer
N=103 --> 125 | Trial primary completion date: Jun 2017 --> Jun 2016 N=90 --> 39 | Not yet recruiting --> Terminated | Trial primary completion date: Jul 2011 --> Nov 2012; Emergence of FOLFIRINOX and slow recruitment
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Tomudex (raltitrexed) / Pfizer, AstraZeneca
Trial completion, Enrollment change, Metastases: Study of Individualized Therapies Selection for Patients With Metastatic Colorectal Carcinoma According to the Therapeutic (clinicaltrials.gov) - Oct 9, 2015
P2, N=29, Completed, Sponsor: Centro Nacional de Investigaciones Oncologicas CARLOS III
N=90 --> 39 | Not yet recruiting --> Terminated | Trial primary completion date: Jul 2011 --> Nov 2012; Emergence of FOLFIRINOX and slow recruitment Recruiting --> Completed | N=80 --> 29